Cytotoxic T Lymphocyte Antigen-4 Gene Variants in Type 2 Diabetic Patients with or without Neuropathy
-
Javad Kiani
,
Saedeh Khadempar
,
Mehrdad Hajilooi
,
Hamzeh Rezaei
,
Fatemeh Keshavarzi
,
Ghasem Solgi
Abstract
Many studies have shown that cytotoxic T lymphocyte antigen-4 (CTLA-4) gene variants are associated with several autoimmune diseases particularly type 1 diabetes. Due to the lack of consistent data for this association with type 2 diabetes (T2D), this study explored the possible influence of CTLA-4 gene polymorphisms at -1722 (T/C), -318 (C/T), and +49 (G/A) positions for susceptibility to T2D in relation with neuropathy. One hundred and eleven unrelated patients with T2D [49 patients with diabetic peripheral neuropathy (DPN) and 62 patients without PDN] and 100 healthy ethnic- and gender-matched controls were included in this study. The dimorphisms at -1722 (C/T), -318 (C/T) and +49 (A/G) for CTLA-4 gene were determined using ARMS-PCR. The CTLA-4 (+49 G/G) and (+49 A/A) genotypes were found to be positively and negatively associated with T2D, respectively (p=0.03). The -318 C/T and T/T genotypes were more frequent in patients than controls and -318 C/C genotype was shown to be protective for T2D (p=0.003). ACT and GTT Haplotypes were less and more frequent in controls and patients, respectively (p=3.86×10-7 and p=2.29×10-5). Genotypes distribution among T2D patients with and without DPN compared to healthy controls showed significantly lower frequencies for -318 C/C and +49 A/A genotypes and significantly higher frequencies for -318 C/T and T/T genotypes as well. Our findings indicate that CTLA-4 (+49 A/G) and (-318 C/T) genotypes could be considered as genetic risk factors associated with susceptibility or protection for T2D.
Stumvoll M, Goldstein BJ, van Haeften TW. Type 2 diabetes: principles of pathogenesis and therapy. Lancet 2005; 365(9467):1333-46.
2. Pickup J, Mattock M, Chusney G, Burt D. NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X. Diabetologia 1997; 40(11):1286-92.
3. Pickup J, Crook M. Is type II diabetes mellitus a disease of the innate immune system? Diabetologia 1998;41(10):1241-8.
4. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 2001;286(3):327-34.
5. Spranger J, Kroke A, Möhlig M, Hoffmann K, Bergmann MM, Ristow M, et al. Inflammatory cytokines and the risk to develop type 2 diabetes results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. Diabetes 2003; 52(3):812-7.
6. Wong C, Ho AW, Tong PC, Yeung C, Chan JC, Kong AP, et al. Aberrant expression of soluble co-stimulatory molecules and adhesion molecules in type 2 diabetic patients with nephropathy. J Clin Immunol 2008;28(1):36-43.
7. Tivol EA, Schweitzer AN, Sharpe AH. Costimulation and autoimmunity. Curr Opin Immunol 1996; 8(6):822-30.
8. Yanagawa T, Hidaka Y, Guimaraes V, Soliman M,DeGroot L. CTLA-4 gene polymorphism associated with Graves' disease in a Caucasian population. J Clin Endocrinol Metab 1995; 80(1):41-5.
9. Chen Z, Fei M, Fu D, Zhang L, Ma Y, Wang Y, et al.Association between cytotoxic T lymphocyte antigen-4 polymorphism andtype 1 diabetes: a meta-analysis. Gene 2013; 516(2):263-70.
10. Shastry BS. SNP alleles in human disease and evolution.J human Genet 2002; 47(11): 561-6.
11. Kouki T, Sawai Y, Gardine CA, Fisfalen M-E, Alegre M- L, DeGroot LJ. CTLA-4 gene polymorphism at position 49 in exon 1 reduces the inhibitory function of CTLA-4 and contributes to the pathogenesis of Graves’ disease. J Immunol 2000; 165(11):6606-11.
12. Braun J, Donner H, Siegmund T, Walfish P, Usadel K, Badenhoop K. CTLA‐4 promoter variants in patients with Graves' disease and Hashimoto's thyroiditis. Tissue Antigens 1998; 51(5):563-6.
13. Gonzalez-Escribano MF, Rodriguez R, Valenzuela A, Garcia A, Garcia-Lozano JR, Nunez-Roldan A. CTLA4 polymorphisms in Spanish patients with rheumatoid arthritis. Tissue Antigens 1999; 53(3):296-300.
14. Mora B, Bonamico M, Indovina P, Megiorni F, Ferri M, Carbone MC, et al. CTLA-4+ 49 A/G dimorphism in Italian patients with celiac disease. Human Immunol 2003; 64(2):297-301.
15. Ma Y, Tang X, Chang W, Gao L, Li M, Yan W. CTLA-4 gene A/G polymorphism associated with diabetes mellitus in Han Chinese. Chin Med Journal 2002;115(8):1248-50.
16. Uzer E, Dilmec F, Akkafa F, Boduroglu O, van Kuilenburg A. Investigation of CTLA-4 and CD28 gene polymorphisms in patients with diabetes mellitus Type 2 using PCR-RFLP in a Turkish population. West Ind Med Journal 2010; 59(3):235-40.
17. Rau H, Braun J, Donner H, Seissler J, Siegmund T, Usadel KH, et al. The Codon 17 Polymorphism of the CTLA4 Gene in Type 2 Diabetes Mellitus 1. J Clin Endocrinol Metab 2001; 86(2):653-5.
18. Qi X, Wang J, Xu Z, Sun J, Keller L, Xu W. Relationship of CTLA-4 gene to latent autoimmune diabetes in adults and Type 2 diabetes: a population-based case-control study. Diabet Manage 2014; 4(2):131-139.
19. England JD, Gronseth GS, Franklin G, Miller RG, Asbury AK, Carter GT, et al. Distal symmetric polyneuropathy: A definition for clinical research Report of the American Academy of Neurology, the American Association of Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. Neurology 2005; 64 (2):199-207.
20. Kiani J, Habibi Z, Tajziehchi A, Moghimbeigi A, Dehghan A, Azizkhani H. Association between serum uric acid level and diabetic peripheral neuropathy (A case control study). Caspian J Intern Med 2014;5(1):17-21.
21. Aguilar F, Torres B, Sanchez-Roman J, Nunez-Roldan A, Gonzalez-Escribano MF. CTLA4 polymorphism in Spanish patients with systemic lupus erythematosus. Hum Immunol 2003; 64(10):936-40.
22. Benjamini Y., Hochberg Y., and Hochberg. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Royal Stat Soci Series B 1995: 57(1): 289–300.
23. Tang ST, Tang HQ, Zhang Q, Wang CJ, Wang YM, Peng WJ. Association of cytotoxic T-lymphocyte associated antigen 4 gene polymorphismwith type 1 diabetes mellitus: a meta-analysis. Gene 2012;508(2):165-87.
24. Parks CG, Cooper GS, Hudson LL, Dooley MA, Treadwell EL, St Clair E, et al. Association of Epstein‐Barr virus with systemic lupus erythematosus: Effect modification by race, age, and cytotoxic T lymphocyte–associated antigen 4 genotype. Arthritis Rheum 2005; 52(4):1148-59.
25. Esteghamati A, Khalilzadeh O, Mobarra Z, Anvari M, Tahvildari M, Amiri HM, et al. Association of CTLA-4 gene polymorphism with Graves' disease and ophthalmopathy in Iranian patients. Eur J Intern Med 2009; 20(4):424-8
26. Ahmadi S, Rostamzadeh J, Khosravi D, Shariati P, Shakiba N. Association of CTLA-4 gene 49A/G polymorphism with the incidence of type 1 diabetes mellitus in the Iranian Kurdish population. Pak J Biol Sci 2013; 16(24):1929-35.
27. Mojtahedi Z, Omrani GR, Doroudchi M, Ghaderi A.CTLA-4 +49 A/G polymorphism is associated with predisposition to type 1 diabetes in Iranians. Diabet Res Clin Pract 2005; 68(2):111-6.
28. Haller K, Kisand K, Pisarev H, Salur L, Laisk T, Nemvalts V, et al. Insulin gene VNTR, CTLA‐4+ 49A/G and HLA‐DQB1 alleles distinguish latent autoimmune diabetes in adults from type 1 diabetes and from type 2 diabetes group. Tissue Antigens 2007; 69(2):121-7.
29. Abe T, Yamaguchi Y, Takino H, Fujita N, Yamauchi‐Degawa M, Ozaki M, et al. CTLA4 gene polymorphism contributes to the mode of onset of diabetes with antiglutamic acid decarboxylase antibody in Japanese patients: genetic analysis of diabetic patients with antiglutamic acid decarboxylase antibody. Diabet Med 2001; 18(9):726-31.
30. Balbi G, Ferrera F, Rizzi M, Piccioli P, Morabito A, Cardamone L, et al. Association of -318 C/T and +49 A/G cytotoxic T lymphocyte antigen-4 (CTLA-4) gene polymorphisms with a clinical subset of Italian patients with systemic sclerosis. Clin Exp Immunol 2007;149(1):40-7.
31. Liu Y, Liang WB, Gao LB, Pan XM, Chen TY, Wang YY, et al. CTLA4 and CD86 gene polymorphisms and susceptibility to chronic obstructive pulmonary disease. Hum Immunol 2010; 71(11):1141-6.
32. Xia B, Crusius JB, Wu J, Zwiers A, van Bodegraven AA, Pena AS. CTLA4 gene polymorphisms in Dutch and Chinese patients with inflammatory bowel disease. Scand J Gastroenterol 2002; 37(11):1296-300.
33. Yousefipour G, Erfani N, Momtahan M, Moghaddasi H, Ghaderi A. CTLA4 exon 1 and promoter polymorphisms in patients with multiple sclerosis. Acta Neurol Scand 2009; 120(6):424-9.
34. Wang XB, Zhao X, Giscombe R, Lefvert AK. A CTLA-4 gene polymorphism at position _318 in the promoter region affects the expression of protein. Genes Immun 2002; 3(4):233–4
35. Shojaa M, Aghaie M, Qorbani M, Khashayar P, Amoli M, Keshtkar AA, et al. Association of the CTLA-4 1722TC polymorphism and systemic lupus erythematosus: a systematic review and meta analysis. Med J Islam Repub Iran 2014; 28:132.
36. Park KS, Baek JA, Do JE, Bang D, Lee ES. CTLA4 gene polymorphisms and soluble CTLA4 protein in Behcet's disease. Tissue Antigens 2009; 74(3):222-7.
| Files | ||
| Issue | Vol 15, No 3 (2016) | |
| Section | Original Article(s) | |
| Keywords | ||
| CTLA-4 antigen Diabetes mellitus Type 2 Genes | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
